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Acute fatty liver of pregnancy (AFLP), a life threatening obstetric emergency, was first described by Sheehan 
in 1940.1 The most common presentation is malaise, 
nausea, vomiting and epigastric pain followed by 
jaundice. Laboratory tests usually demonstrate high 
bilirubin levels, deranged liver and renal functions, 
coagulopathy and hypoglycaemia. At presentation, 
one should keep in mind other pregnancy related 
liver diseases that mimic AFLP such as HELLP 
syndrome: haemolysis (H), elevated liver enzymes 
(EL) and low platelet count (LP), and intrahepatic 
cholestasis of pregnancy. Liver biopsy is the gold 
standard for diagnosing AFLP, but due to the 
presence of coagulation abnormalities diagnosis is 
usually made by clinical and laboratory findings. 
Bleeding and disseminated intravascular coagulation 
(DIC) are one of most common complications. 
Case Report
A 36 year-old healthy woman, gravida 3 para 2, 
presented to a peripheral hospital at 34 weeks 
gestation with a 3-day history of malaise, nausea, 
vomiting and abdominal pains. Her pregnancy 
had been uncomplicated. On admission, her vitals 
appeared to be stable, but her blood pressure was 
150/90 mmHg with no proteinuria. The results 
of the complete blood count was as follows: 
haemoglobin 13.4 g/dl; white blood count 22 x 
109/L, and platelets, 227 x 109/L. The biochemical 
markers were as follows: total bilirubin 122.8 
µmol/L; serum aspartate aminotransferase (AST) 
118.9 IU/L; serum alanine aminotransferase (ALT) 
129.8 IU/L, and creatinine 158.5 µmol/L. The 
coagulation profile was as follows: prothrombin 
time (PT) 13 sec; activated partial thromboplastin 
time (APTT) 41 sec.
The patient underwent an emergency caesarean 
section because of a non-reassuring fetal heart 
tracing. The outcome was a live male baby with 
good Apgar scores. The next day, the patient started 
bleeding profusely through the vagina and her 
haemoglobin dropped to 4.9 g/dl; the platelet count 
was 25 x 109/L and fibrinogen 0.5 g/L. She was 
assessed, but no cause of bleeding identified. 
She was taken to the operating room and an 
exploratory midline laparotomy was performed. No 
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حالة ال منطية للكبد الدهن احلاد يف احلمل 
نهال الريامي، عبد اهلل احلارثي، فهميدا �ضياء
امللخ�ص:ُيَعّد الكبد الدهني احلاد يف احلمل من احلالت الطارئة التي تهدد احلياة. ت�صمل الأعرا�ص الأكرث �صي�عا: الت�عك والغثيان والتقي�ؤ 
والأمل ال�رس�ص�يف يتبعها الريقان. ينبغي اإجراء الت�صخي�ص مبكرا والإ�رساع بالعالج والرعاية نظرا لرتفاع معدل وفيات الأمهات وحديثي 
ال�لدة. ندرج هنا و�صف حلالة ل منطية من الكبد الدهني احلاد يف احلمل ونناق�ص العالج وامل�صاعفات لهذه احلالة النادرة من ال�صطراب.
مفتاح الكلمات: الكبد الدهني احلاد يف احلمل ؛ النزف بعد الولدة؛ تخرث الدم داخل الأوعية، تقرير حالة، ُعمان.
abstract: Acute fatty liver of pregnancy (AFLP) is a life threatening obstetric emergency. The most common 
presentation is malaise, nausea, vomiting and epigastric pain followed by jaundice. Due to high maternal and 
perinatal mortality, early diagnosis, prompt delivery and supportive care are required. We report an atypical case of 
AFLP and discuss the management and complications of this rare obstetric disorder.
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source of bleeding was identified intraoperatively 
and the abdomen was packed, closed and an 
intraperitoneal drain was inserted. A hysterectomy 
was not performed and no other intervention was 
done. 
The patient was then transferred to the intensive 
care unit (ICU) at Sultan Qaboos University, 
tertiary hospital, Oman, after receiving a total 
of 10 units of packed red blood cells, 19 units of 
fresh frozen plasma, 7 units of cryoprecipitate and 
7 units of platelets. She was ventilated and was 
on intravenous dopamine infusion. The patient 
was bleeding profusely from her intraperitoneal 
Jackson-Pratt (J-P) drain. The laboratory findings 
on admission at our hospital were as follows:  Hb 
12.4 g/dl; platelets 56 x 109/L; PT 23 sec; APTT 40 
sec; fibrinogen 1.5 g/L; total bilirubin 155 µmol/L; 
AST 123 IU/L; ALT 123 IU/L, and creatinine 163.9 
µmol/L. The patient required further replacement 
of blood products. At our hospital, she received a 
total of 5 units of packed red blood cells, 5 units 
of fresh frozen plasma, 11 units of cryoprecipitate 
and 10 units of platelets. Two units of recombinant 
activated factor VII (rFVIIa) were given to her and 
the bleeding lessened thereafter. She was taken to 
the operating room 24 hours after admission for 
removal of the abdominal packs. At the time of 
surgery, it was noted the abdominal packs were 
foul smelling and adherent to the serosal layers. The 
abdominal wall was bruised, but no active bleeding 
was observed. Since there was no active bleeding, 
a hysterectomy was not performed, the packs were 
removed and abdomen was irrigated well and 
closed in layers. During the patient’s ICU stay, she 
was on intravenous labetalol infusion for 48 hours 
to control her blood pressure. She was extubated 
on day 4 and moved to the ward on day 8 of 
admission.
The patient’s status improved gradually, but she 
remained severally jaundiced with high bilirubin 
levels, mainly of the conjugated type (maximum 
total bilirubin level of 280), raised liver enzymes 
remaining in the hundreds and hypoalbuminemic 
(15 g/dl). Viral hepatitis screening was done, but 
was negative. The dilemma was the amount of 
serous fluid drainage, first from the J-P drain that 
was removed on day 8 of admission and then 
from the patient’s wound site. Clinical assessment 
and several investigations were performed 
including creatinine levels of the draining fluid, 
intravenous pyelogram, and ultrasound and 
computed tomography (CT) scans of the abdomen 
that excluded wound dehiscence, urinoma and 
seroma. On the bases of her clinical presentation 
including her signs, symptoms, massive bleeding 
and laboratory findings, the diagnosis of AFLP 
was made and supportive care continued. Further 
investigations with liver ultrasound and CT scans 
did not show evidence of fatty changes of the liver 
and a liver biopsy was not performed. 
On day 18 of admission, the patient was febrile 
and her wound grew a Pseudomonas species 
infection that was treated with intravenous 
antibiotics (meropenem). On day 21 of admission, 
complete wound dehiscence was found and an 
emergency surgery was performed. It was noted 
during the surgery that there were lots of adhesions, 
the liver was frozen with multiple adhesions, the 
bowel was inflamed and the rectus fascia was not 
healthy. After adhesiolysis and extensive washing 
of the abdominal cavity with normal saline, a mass 
closure of the abdomen was performed using 
tension sutures. Postoperatively, the patient did 
well. The wound healed with the assistance of the 
vacuum assisted closure (VAC) system. The sutures 
were removed after 4 weeks and she was discharged 
home. She was monitored closely in the outpatient 
clinic and on her six weeks follow-up, the liver 
enzymes, bilirubin and albumin levels were normal 
and she was off antihypertensive medications.
Discussion
Hypertensive and liver disorders of pregnancy 
comprise a spectrum of conditions associated 
with adverse fetomaternal outcomes.1 The 
patient’s initial presentation may vary during 
the antepartum, intrapartum and even the 
postpartum period. Clear understanding of 
the pathophysiology and mechanism of these 
disorders in pregnancy is very important. Although 
severe preeclampsia is commoner than AFLP and 
other liver disorders related to pregnancy, our 
patient's presentation and laboratory test results were 
in favour of an AFLP diagnosis. Ch'ng et al. first set 
the Swansea criteria for diagnosing AFLP that have 
been used by many institutions.2,3 Six or more of the 
following features are used to diagnose AFLP in the 
absence of other explanation: vomiting; abdominal 
pain; polydipsia/polyuria; encephalopathy; 
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elevated bilirubin >14 µmol/L; hypoglycaemia <4 
mmol/L; elevated urate >340 µmol/L; leukocytosis 
>11x109/L; ascites or bright liver on ultrasound; 
elevated tramsaminases; elevated ammonia >47 
µmol/L; renal impairment creatinine >150 µmol/L; 
coagulopathy (PT >14 sec or APTT >34 sec), or 
microvesicular steatosis on liver biopsy. Using these 
criteria we anticipated the diagnosis of AFLP. The 
patient had vomiting, abdominal pain, elevated 
bilirubin and transaminases, elevated creatinine 
and coagulopathy at presentation. A patient with 
severe preeclampsia/HELLP will usually present 
with proteinuria.  
AFLP was first described by Sheehan in 1940.1 
The aetiology of the disease is unknown with an 
incidence of 1 in 10,000 to 1 in 15,000.5 It is a life 
threatening obstetrical emergency that can lead 
to high maternal and perinatal morbidity and 
mortality. Due to the development of more rapid 
diagnosis tools and early termination of pregnancy, 
the maternal mortality rate due to this disease has 
decreased from 80–85% to 7–18% and the fetal 
mortality rate from 50% to 9–23%.6-8  The disease 
usually presents in the first pregnancy and in the 
third trimester with a mean gestational age of 
34–37 weeks.9,10 The signs and symptoms at initial 
presentation may vary, making the diagnosis of this 
disease difficult, or there might be delay in diagnosis. 
Similarly, the differential diagnosis may be difficult 
in a patient with abnormal hepatic function in 
pregnancy since a number of pathologies such as 
HELLP syndrome, viral hepatitis and hormone-
induced cholestasis share some of the same 
symptoms and signs. 
The diagnosis of AFLP remains challenging since 
there is no specific non-invasive diagnostic test to 
identify it. Ultrasound and CT scans of the liver 
have been used, but the specificity and sensitivity 
of these  studies are insufficient to make a diagnosis 
and the likelihood of false negative results is high.11 
Our patient had normal liver ultrasound and CT 
scan results.
Liver biopsy is the gold standard test, but it 
is invasive and requires a patient with normal 
coagulation status.4,5,12 The clinical presentation of 
both AFLP and HELLP syndrome are very similar 
but nausea, vomiting, epigastric pain and jaundice 
are more commonly seen in AFLP patients.5 
Although AFLP is an uncommon disease, our 
patient’s presentation and the development of 
jaundice with chronic hypoalbuminemia made 
this diagnosis more likely. Moreover, the patient 
developed DIC requiring massive blood transfusion 
(total of 76 units), making the diagnosis of AFLP 
more likely. DIC is seen in about 80–100% of 
patients with AFLP as opposed to 21% of patients 
with HELLP syndrome.5,12-14 The DIC might be a 
severe and potentially fatal complication of AFLP. 
The main cause of the coagulopathy leading to 
DIC in patients with AFLP is the severe hepatic 
dysfunction. It is less likely to be a complication for 
patients with other obstetrical or medical disorders 
such as HELLP syndrome. Early identification 
and correction of the coagulopathy before any 
obstetrical procedure is very important. When 
the patient presented to our ICU, after having two 
surgeries within 24 hours, it was very difficult to 
make the decision to take her back to the operating 
room to control her bleeding. We continued 
replacing her with blood products and decided 
to give her rFVIIa and observe if the latter would 
control the bleeding. Fortunately, the bleeding 
settled and the patient stabilised after receiving two 
doses of rFVIIa.
There are an increasing number of case reports 
in the literature describing the successful “off-
label” use of rFVIIa (NovoSeven, Novo Nordisk, 
Denmark) in the treatment of massive postpartum 
haemorrhage (PPH) refractory to conventional 
medical and surgical therapy.15 The rationale for 
the use of rFVIIa in this setting is based on the 
observation that it directly activates factor X on the 
surface of activated platelets at the site of injury, 
factors VIII, and IX. This results in a “thrombin 
burst” with the conversion of prothrombin into 
large amounts of thrombin and the local formation 
of a stable fibrin clot that may control bleeding.16 
A recent systematic review was undertaken by 
a group in Italy looking at the effects and role of 
rFVIIa in patients with massive PPH.17 Nine studies 
met the inclusion criteria and there were 272 
patients involved. The group made the following 
recommendations: 1) Consider the use of rFVIIa in 
cases of massive PPH refractory to medical therapy 
including replacement of other blood products and 
even after a conservative/invasive surgical approach 
such as internal iliac or uterine artery ligation fails; 
2) Consider a second dose of rFVIIa (90 mg/kg IV 
bollus over 3–5 min) if there is no response after 
20 minutes from the first dose, and 3) If bleeding 
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persists after 2 doses of rFVIIa, consider performing 
a hysterectomy.
Conclusion
Despite the critical condition at presentation, 
and the complications she went through such as 
DIC, chronic hypoalbuminemia, infection and 
burst abdomen, our patient finally went home in 
a good condition. Early diagnosis of obstetrical 
emergencies, prompt therapy, adequate supportive 
care and a multidisciplinary approach are the key 
elements for a good outcome.
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